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Abstract
Significant progress is being made concerning the development of oligonucleotides as therapeutic
agents. Studies with antisense, siRNA, and other forms of oligonucleotides have shown promise in
cellular and animal models and in some clinical studies. Nonetheless our understanding of how
oligonucleotides function in cells and tissues is really quite limited. One major issue concerns the
modes of uptake and intracellular trafficking of oligonucleotides, whether as ‘free’ molecules, or
linked to various delivery moieties such as nanoparticles or targeting ligands. In this review we
examine the recent literature on oligonucleotide internalization and subcellular trafficking in the
context of current insights into the basic machinery for endocytosis and intracellular vesicular
traffic.
Introduction
The concept of using oligonucleotides as therapeutic agents emerged more than three
decades ago when antisense molecules were first described 1. More recently enthusiasm for
this approach was rekindled by the discovery of RNA interference 2 and of the ability to
activate this process using exogenous short double stranded RNAs (siRNAs) 3. The potential
of oligonucleotide-based therapeutics has been further reinforced by new discoveries
concerning the complex roles of non-coding RNAs in regulating many facets of genome
function 4. Currently multiple approaches are available for employing oligonucleotides to
influence the extent and pattern of gene expression. This includes using conventional
antisense or siRNA molecules to selectively degrade mRNA 5,6, antagomirs to block the
actions of miRNAs 7, splice shifting oligonucleotides to alter gene expression patterns 8,
decoys to block transcription factors 9, CpG rich oligonucleotides to stimulate the immune
system 10, and triplex oligonucleotides for targeted mutagenesis 11. Each of these
approaches has benefited immensely from recent progress in oligonucleotide chemistry that
has resulted in the creation of stable and potent molecules 12-14. However, despite many
research advances and the initiation of multiple clinical trials 5,15, the evolution of
oligonucleotides as therapeutic agents has been hindered by the fact that delivery of these
large, usually highly charged, molecules to their intracellular sites of action is a very
challenging task 16,17. In this article we review current information concerning the uptake of
oligonucleotides and their intracellular trafficking. We consider the fate of ‘free’
oligonucleotides, of conjugates with various targeting ligands, and of oligonucleotides
associated with nanoparticle carriers. The emphasis will be on events at the cellular and
subcellular level rather than on whole animal pharmacokinetics and biodistribution, although
some informative in vivo studies will be discussed. A theme that will pervade this article is
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molecules and that thus influence the therapeutic potential of exogenously administered
oligonucleotides.
1. Overview of Endocytotic and Trafficking Pathways
Although it is commonly accepted that antisense and siRNA oligonucleotides usually enter
cells via endocytosis, this broad statement masks the complexities inherent in multiple
pathways of internalization and subsequent intracellular trafficking. Here we will describe
some of these events and discuss the implications for oligonucleotide pharmacology. We
will also emphasize the intricate and highly selective protein machinery that underlies all
aspects of endocytosis and trafficking.
a. Pathways of endocytosis and the associated protein machinery
Over the last few years it has become clear that there exist multiple pathways of endocytosis
in addition to the archetypal clathrin coated pit pathway 18-20. A diagram depicting some of
these pathways is shown in Figure 1. In classical clathrin mediated endocytosis cell surface
receptors and their associated ligands interact with adapter proteins including AP-2, and
with a host of accessory factors, that cluster the receptors into specialized membrane areas
subtended by a network of clathrin triskelions. The clathrin network, as well as specialized
BAR domain proteins such as SNX9 and amphiphysin that sense and promote membrane
curvature, contribute to invagination; this is followed by pinching off of a clathrin-coated
vesicle through the agency of the dynamin GTPase 21. The coated endosome quickly
uncoats under the influence of a set of proteins including auxilin and hsc70 and now the
uncoated vesicle is ready to begin its intracellular journey. Many important receptors and
ligands are internalized via the clathrin pathway including LDL, transferrin, and many
activated G Protein Coupled Receptors 20,22.
The caveolar pathway has also evoked a great deal of interest 23. Many cells display small
invaginations that are rich in cholesterol and sphingolipids and that contain caveolin1, a
21kD protein that inserts a hydrophobic hairpin into the membrane while both N- and C-
termini are cytosolic. Additionally, the cavins, are coat proteins that help stabilize caveolar
structures. There is some controversy as to whether caveolae generate independent
intracellular vesicles or whether they remain as tubular structures linked to the plasma
membrane; however, substantial evidence suggests that caveolae generate vesicles that can
contribute to intracellular membrane traffic. In general caveolar structures are smaller (<100
nanometers) than other forms of endocytotic vesicles, which may reach several hundred
nanometers in diameter. Cholera toxin (CTxB), SV40 virus, and GPI-linked membrane
proteins are among the entities that are preferentially internalized via caveolae (however,
some of these moieties are also internalized by other pathways). It seems likely that dynamin
is involved in the disjunction of caveolae, but the evidence is not as clear as for the clathrin-
mediated pathway. Many proteins in addition to caveolin have been observed to be
associated with caveolae; in particular these structures are rich in molecules involved in
signal transduction 24-26.
Recently a number of clathrin- and caveolin- independent pathways have been delineated to
various degrees. These pathways are often defined either in terms of the morphologies of the
vesicles they generate or in terms of the cargo that is preferentially internalized. For
example, the flotillins are membrane-inserted proteins that may be involved in ordering lipid
domains and subsequent endocytosis similarly to caveolin. Both CTxB and GPI-linked
proteins have been associated with flotillin-rich membrane microdomains. Interestingly
some reports suggest that dynamin is not needed for internalization of cargo via flotillin
containing vesicles 27. Thus the flotillin pathway represents one example of a clathrin and
caveolin independent internalization mechanism.
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Another key internalization mechanism is the CLIC/GEEC pathway that seems to be
particularly important for fluid phase endocytosis 20. The acronym is for Clathrin and
Dynamin Independent Carriers (CLIC)/GPI-AP Enriched Early Endosomal Compartments
(GEEC). This pathway gives rise to high volume tubular endosomes that are rich in GPI-
proteins (including the folate receptor FRα) and that typically contain fluid phase markers
such as dextrans. As the name implies, dynamin is not necessary for the pinching off of
these vesicles. Instead membrane scission may be mediated by GRAF1, a BAR domain
containing GTPase activating protein 28.
Additional clathrin and caveolin independent pathways exist 20,28. This includes a pathway
involved in the internalization of a form of the IL2-Receptor, certain potassium channels,
and the FCεR1 immunoglobulin receptor. This pathway involves dynamin-mediated
disjunction of vesicles from the plasma membrane; as well this pathway seems to be
regulated by protein kinases of the PAK family. Another pathway that generates both
vesicular and tubular structures has been implicated in the internalization of MHC class I
histocompatibility proteins; a role for dynamin has not yet been found for this pathway.
Macropinocytosis describes a process by which cell protrusions pinch off large volumes of
extracellular fluid and is thus an important aspect of fluid phase endocytosis 29. It is also
involved in the internalization of clustered, activated receptor tyrosine kinases. Generation
of these relatively large structures involves the actinomyosin contractile machinery and is
thus associated with typical regulators of such processes including the Rac GTPase and PAK
family kinases, but probably not dynamin. Other large volume internalization mechanisms
such as phagocytosis and entosis come into play in specialized cells or unusual
circumstances but these are unlikely to play much of a role in the processing of
oligonucleotides in the majority of cell types 20. The actin cytoskeleton plays an important
role in most of the endocytotic processes described above; however, not all internalizations
require actin. Thus certain arenaviruses enter cells by a pathway that is independent of
clathrin, caveolin, dynamin and actin 30. Interestingly we recently found that
phosphorothioate antisense oligonucleotides seem to enter cells by this pathway as well 31.
In summary, we know of multiple pathways for endocytosis with more probably remaining
to be discovered. This provides daunting complexity but also exciting opportunities for
oligonucleotide pharmacology. Thus by targeting antisense or siRNA to specific cell surface
receptors it is possible to influence the initial route of internalization. As we will discuss
below, this may have important implications for further processing and for the ultimate
biological effect of the oligonucleotide.
b. Trafficking downstream of initial internalization- Rabs, Tethers and Snares
Whether presented in unmodified form, as a chemical conjugate, or associated with a
nanocarrier, an oligonucleotide entering a cell in an endosome encounters a complex maze
of intracellular pathways that can lead to many destinations and that is regulated by intricate
protein machinery 32. Key subcellular membrane bound compartments include early and
recycling endosomes, late endosomes/multi-vesicular bodies, lysosomes, the Golgi
apparatus and the endoplasmic reticulum. (see Figure 1). Trafficking is not a random
process, but rather it is a carefully orchestrated ballet that allows the cell to transport
endogenous and exogenous materials to the most appropriate place. Many pathogens have
learned to exploit these events; for example certain viruses as well as many bacterial toxins
engage the so-called retrograde transport process 33 and are thus delivered to the trans-Golgi
compartment from which they seem to have ready access to the cytosol. Ultimately this is
the goal of oligonucleotide delivery as well, to leave membrane bound compartments and
access the cytosol and nucleus. It seems increasingly clear that appropriate manipulation of
endocytotic and trafficking pathways can help attain this goal. For example, inhibition of
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intracellular protein kinase A activity with small molecule drugs can prevent trafficking into
the late endosomal/lysosomal compartments in cellular delivery of nucleic acids via
polyplexes and lipoplexes, thus improving the transfection efficiency 34.
We only partially understand how endocytotic cargos are delivered to particular subcellular
compartments. Many of the internalization pathways described above converge at the stage
of early endosomes. This raises the question of how receptors, ligands and cargo that have
been internalized by different initial endocytotic mechanisms traffic to different subcellular
destinations. Recent evidence suggests that membrane domains originating from different
internalization pathways maintain their identity within early endosomes, thus setting the
stage for specific sorting and trafficking to distinct downstream destinations 28.
The past few years have seen enormous progress in understanding the molecular
mechanisms of intracellular trafficking. All membrane traffic proceeds by the same basic
steps: (a) a coated vesicle is pinched off from a larger donor membrane compartment; (b) the
vesicle uncoats allowing the display of tethering and fusion proteins; (c) the vesicle is
carried to its destination along ‘tracks’ provided by actin- or tubulin- based cytoskeletal
structures; (d) the vesicle recognizes its target membrane compartment using tethering
proteins and then utilizes SNARE proteins to complete the fusion process and deliver
membrane and contents to the target compartment 32. A simplified diagram of this process is
shown in Figure 2. There are numerous variations of the overall theme and still some
uncertainty about the exact sequence of events, but the overall picture is quite clear.
For a more detailed discussion of intracellular trafficking mechanisms it is necessary to
introduce the Rab proteins. The Rabs comprise a large (>60) family of GTPases that serve as
molecular switches to regulate multiple aspects of intracellular vesicular traffic 35,36. In their
active GTP loaded form Rabs bind to and modulate the function of downstream effector
proteins. In their inactive GDP loaded form they associate with Rab-GDI (Rab GDP
Dissociation Inhibitor) proteins that both stabilize the inactive form and serve as chaperones
to regulate the balance between cytosolic and membrane bound Rab. As with other small
GTPases, the equilibrium between active and inactive forms is regulated by Rab specific
GEFs (Guanine Nucleotide Exchange Factors) and GAPs (GTPase Activating Proteins).
Rabs serve many different roles in regulating intracellular trafficking including vesicle
uncoating, vesicle movement along cytoskeletal tracks, and the ultimate fusion events. For
example, Rab5 regulates the uncoating of clathrin-coated vesicles during classical receptor
mediated endocytosis while Rab 27A links melanosomes to the myosin Va motor protein via
a Rab-binding adaptor protein. Rabs also associate with tethering proteins, a good example
being the association of Rab1 with Golgin-type tethers. Because of their high specificity Rab
proteins serve as excellent markers of individual membrane trafficking pathways. Thus
Rab5 is associated with the movement of clathrin coated vesicles to the early endosome, Rab
4 with the early endosome and recycling to the plasma membrane, Rab7 with late
endosomes/lysosomes, Rab9 with late endosome to Golgi traffic, and Rab11 with a slowly
recycling perinuclear endomembrane compartment (see Figure 1). However, a complex
aspect of Rab function concerns the formation of ‘Rab domains’ within particular
endosomes. Thus studies using low levels of expressed green fluorescent protein-Rab
chimeras, have shown that different Rab proteins localized on the same organelle can
occupy distinct membrane microdomains 35. This segregation of Rabs may play a role in the
endosomal sorting processes discussed above 28.
As mentioned above, the initial event in intracellular trafficking is the pinching off of a
coated vesicle from a donor membrane. The formation of clathrin coated vesicles (CCVs) at
the plasma membrane is a good example, but other types of coats exist such as the COPI and
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COPII coats of the Golgi and ER. Disjunction of the coated vesicle is accomplished by
dynamin in the case of CCVs, but by other mechanisms as well. For example, budding off of
vesicles from late endosomes to the trans-Golgi is accomplished by the retromer complex
with its BAR-domain containing SNX proteins 37.
Tethering proteins impart selectivity to vesicle traffic by supporting preferential interactions
between the vesicle and its ultimate target membrane compartment. There are two broad
classes of tethering molecules; the coiled-coil tethers such as the Golgins and the multi-
subunit tethers 38. Tethers are thought to bridge membranes and promote fusion by binding
to both Rab proteins and to SNARES. There is some uncertainty about when and how
tethering proteins associate with trafficking vesicles, particularly whether tethers interact
with vesicle coat proteins or if tethering takes place after uncoating 32,35.
The ultimate transfer of both the membrane material and the contents of the shuttle vesicle
to the recipient compartment is accomplished via a fusion process mediated by SNAREs
(soluble N-methylmaleimide sensitive factor attachment protein receptors) 39. After
recognition is accomplished by tethering proteins, SNARES on the vesicle (v-SNARES)
interact with SNARES on the target membrane (t-SNARES) to form a four-helix bundle that
undergoes conformational change to induce membrane fusion. There is considerable
specificity in this process since only specific cognate pairs of v- and t-SNARES will sustain
fusion. Resegregation of the v-SNARES and t-SNARES is mediated by the ATP-dependent
NSF/SNAP protein complex.
c. Escape from endosomes during intracellular trafficking
The complex machinery described above is designed to move endogenous molecules to
specific membrane destinations within the cell. Although it is quite efficient and selective,
nonetheless there is some opportunity for molecules to escape from endomembrane
compartments to the cytosol. Intracellular trafficking involves a highly dynamic flux of
membrane vesicles that engage in a multitude of fusion and disjunction events. In recent
years fusion mechanisms in both natural membranes and artificial lipid membranes have
been studied in great detail 40,41. While this literature is largely beyond the scope of this
review, there are a few key points to be noted. First, fusion involves localized stress on the
fusion partners including the formation of non-bilayer lipid domains 40,42. Second, there is
good evidence that non-bilayer regions of membranes can be much leakier than bilayer
regions 43,44. Third, many enveloped viruses fuse with cells via specialized membrane
interacting proteins that, while differing in sequence, act in a manner similar to cellular
SNARE proteins; the influenza virus fusion protein is a good example 45. In many cases
these proteins can also induce increases in membrane permeability 46. Therefore there is an
intrinsic relationship between the fusion events inherent in intracellular trafficking and
transient leakage of vesicular contents (see Figure 2). Thus the innate activity of
oligonucleotides taken up by cells is likely due to a modest amount of continuous leakage
from endomembrane compartments that spontaneously occurs during intracellular
trafficking, while much of the current technology for enhancing oligonucleotide effects is
aimed at increasing the extent of endosomal release, as discussed below.
d. Nuclear entry
Antisense oligonucleotides encounter their pharmacological targets in the nucleus, but
nuclear entry may not be the rate-limiting step for oligonucleotide pharmacology. Studies
have shown that oligonucleotides, particularly those with phosphorothioate backbones, are
able to continuously shuttle between the nucleus and the cytoplasm. This is an active process
mediated by nuclear pore structures; however, it does not require classical nuclear
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localization signals. For conventional phosphodiester oligonucleotides both passive
diffusion and active transport have been described as nuclear entry mechanisms 47,48.
2. Uptake and Trafficking of ‘Free’ Oligonucleotides
There has been considerable work done trying to understand the cellular uptake, trafficking
and tissue distribution of oligonucleotides themselves, absent any specific targeting or
carrier mechanisms. Some of the earlier literature has been covered elsewhere 49 and more
recent reviews have updated information on the pharmacokinetics and biodistribution of
antisense and siRNA 5,50. While uncharged oligonucleotides such as morpholino and
peptide nucleic acid derivatives, as well as most forms of siRNA, are rapidly excreted via
the kidney, phosphorothioate (PS) oligonucleotides display substantial binding to plasma
proteins and cells and are thus retained in the body for longer periods. Preferential in vivo
uptake by certain cell types, particularly kidney proximal tubule cells and liver Kupffer
cells, has been noted both for PS antisense compounds and for siRNA 51,52. Recent
publications have provided new insights into the uptake and trafficking of ‘free’ or ‘naked’
oligonucleotides. Thus a study using phosphorothioate antisense oligonucleotides in a
transformed liver cell line and in murine livers has suggested the co-existence of productive
and non-productive routes of uptake 53. The non-productive pathway seems to involve
trafficking to lysosomes, while the pathway that results in RNase H dependent antisense
effects involves trafficking that eventually leads to interaction with cellular pre-mRNA. A
somewhat confusing observation is that the productive pathway is not blocked by siRNA
targeting clathrin but is blocked by siRNA targeting AP2M1 an adapter protein in the
clathrin endocytotic pathway. In any case this study provides one of the most detailed
accounts to date of the subcellular fate of free oligonucleotides in cells and tissues. Other
interesting studies, both in cell culture and in mouse models, have involved the so-called
‘gymnotic’ uptake of antisense oligonucleotides modified with LNA (locked nucleic acid)
moieties 54,55. In contrast with the previously mentioned study, which used nanomolar
concentration of PS oligonucleotides, the antisense effects of ‘naked’ LNA usually required
micromolar concentrations. Subcellular distribution studies surprisingly suggested that the
deoxy LNA compounds became associated with P-bodies that are usually thought to be sites
of siRNA action 54.
There have been many attempts to identify endogenous receptors for antisense or siRNA
molecules; however, much of this literature is problematic and no direct evidence for their
involvement in oligonucleotide trafficking has been provided. Integrins of the beta2
subclass 56 as well as scavenger receptors 51 have been suggested as candidates, but this is
controversial 57. A putative oligonucleotide transporter has also been described 58,59 but
there has not been a great deal of confirmatory work on this finding by other groups.
Another interesting candidate is the mammalian homolog of the double-stranded RNA
(dsRNA) transport protein SID-1 found in Caenorhabditis elegans 60. SID-1 clearly plays a
key role in the spread of RNA interference from cell to cell in some invertebrates. However,
initial reports of a role for SID-1 in uptake of siRNA by mammalian cells 61-63 have not
been followed by more advanced mechanistic studies. An interesting variant on
oligonucleotide delivery involves the stimulation of siRNA uptake by phosphorothioate
oligonucleotides 64; the phenomenon seems clear although the underlying mechanism is still
not fully resolved.
The most convincing examples of cellular receptors for oligonucleotides involve the Toll-
Like Receptor (TLR) family 65,66. As a simplistic summary, TLR9 binds DNA having CpG
motifs, TLRs7/8 bind single stranded RNA, while TLR3 binds double stranded RNA.
Although these TLRs are usually found within endosomes rather than at the cell surface, in
some cases they seem to be able to assist in the accumulation of oligonucleotides by cells.
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For example, as discussed in more detail below, a CpG oligonucleotide was able to
substantially enhance the cell uptake and effect of a conjugated siRNA 67.
In summary, at this point there is only a limited amount of information about the
mechanisms involved in cell uptake and subcellular trafficking of ‘free’ oligonucleotides,
with many contradictions needing to be resolved. This seems an important topic to address
since most of the clinical studies with antisense or siRNA to date have used ‘free’
compounds.
3. Uptake and Trafficking of Conjugates and Complexes of
Oligonucleotides with Cell Penetrating Peptides
Over the last decade there has been substantial interest in using so called ‘cell penetrating
peptides’ (CPPs) for the delivery of oligonucleotides. CPPs (sometimes called ‘protein
transduction domains’) are peptides, usually rich in cationic residues, that purportedly have
the ability to cross membranes and in doing so convey attached cargoes into the cytosol. The
TAT and Antennepedia peptides are the archetypal forms, but a large variety of new CPPs
have been described more recently 68-70. Originally it was thought the CPPs could directly
translocate across the plasma membrane (and some recent publications still support this
view 71,72). However, most reports suggest that cationic CPPs bind initially to negatively
charged proteoglycans at the cell surface, are internalized into endosomes, and may then
escape from those structures. Studies have linked the entry pathway of TAT or its conjugates
to clathrin-mediated endocytosis 73, macropinocytosis 74, or calveolar endocytosis 75 in
various cell types and experimental circumstances. In any case, it is clear that the nature of
the attached cargo plays a major role in CPP uptake mechanisms and in the effectiveness of
cytosolic delivery 76,77. In general, as might be anticipated, smaller cargos are delivered
more effectively; for example, TAT-containing proteins are mostly trapped in cytoplasmic
vesicles after cellular uptake, while the TAT-peptide conjugates distribute throughout the
cell 76.
There have been numerous studies of both chemical conjugates and noncovalent complexes
of antisense and siRNA with CPPs. Work on the chemical conjugates has been the subject of
recent reviews 78,79. In general, conjugates of CPPs with charged oligonucleotides have not
proven to be very promising, while conjugates with uncharged oligonucleotides such as
morpholinos or peptide nucleic acids (PNAs) have displayed more activity. This may be of
particular interest in the context of splice-shifting oligonucleotides (SSOs) that can be used
to correct or modify RNA splicing processes 8. Recent work with conjugates of novel CPPs
to PNA 80 or morpholino 81 SSOs have shown good splice-correction results in cell culture,
and promising therapeutic performance in mouse models of Duchenne muscular
dystrophy 82,83. Another interesting approach has been to make CPP-oligonucleotide
conjugates that also contain a lipid moiety 84; this seems to lead to enhanced endosomal
escape and thus greater efficacy of the conjugated PNA SSO.
Despite some early studies to the contrary, chemical conjugation of classic antisense or
siRNA oligonucleotides to CPPs has been problematic. For this reason a number of
laboratories have turned to non-covalent complexation of CPPs with anionic
oligonucleotides to form various nanoparticles. This strategy has been the subject of recent
reviews 85,86. The complexation of cationic CPPs with oligonucleotides results in the
formation of nanoscale particles 87-89. These entities can be very effective in delivering
oligonucleotides; for example siRNA complexed with a CPP modified with a
lysosomotropic chloroquine analog provided strong ‘knockdown’ in a number of difficult to
transfect cell lines 90. SSOs complexed with PepFect 14, a new stearylated CPP, induced
higher splicing correction than the commercially available lipid-based vector Lipofectamine
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2000, and the CPP/SSO complexes could be incorporated into solid dispersions so that the
stability was improved significantly 89. CPP/oligonucleotide complexes have also been
tested in vivo 87,90. However, there are some obvious concerns about systemic
administration of such nanoparticles in terms of rapid clearance by the reticuloendothelial
system, limited biodistribution, and toxicity 17. Perhaps the proponents of CPP/
oligonucleotide complexes can adapt approaches from other nanoparticle technologies, such
as use of PEG to improve biodistribution characteristics.
There has been only limited investigation of basic uptake and trafficking mechanisms of
CPP oligonucleotide conjugates or complexes. One type of CPP/siRNA complex has
received extensive biophysical analysis leading to the suggestion that these complexes can
enter cells by non-endocytotic means 85; however, physical analysis may offer only limited
insights into cellular mechanisms. Other studies of these complexes using pharmacological
inhibitors also suggested non-endocytotic uptake pathways 91. In contrast, a recent study
using complexes of novel CPPs with 2’-O-Methy-phosphorothioate splice switching
oligonucleotides presents a very different picture, with the initial uptake occurring mainly by
clathrin-mediated endocytosis as discerned by using pharmacological inhibitors of uptake
pathways 92. The effectiveness of the splice correction was not dependent on total uptake
but rather on increased release of the SSO from endosomes. There have been some relatively
recent mechanistic studies of chemical conjugates of CPPs with SSOs 80 also suggesting cell
entry via clathrin-mediated endocytosis. Unfortunately most of the studies of complexes or
conjugates of CPPs with oligonucleotides have relied on use of rather non-specific
pharmacological inhibitors to evaluate uptake mechanisms. While this is a useful first step,
such studies should be followed up by further analysis using molecular means to alter uptake
and trafficking pathways, and by more detailed studies of co-localization with known
markers of intracellular membrane compartments.
4. Uptake and Trafficking of Receptor Targeted Ligand-Oligonucleotide
Conjugates
In addition to the CPP-oligonucleotide conjugates described above, there has been
substantial work involving other covalent modifications of antisense and siRNA to enhance
their biological properties, as summarized in several recent reviews 93-96. Much of this has
focused on conjugation with cholesterol or other lipophilic moieties to increase
oligonucleotide lifetime in the circulation and to promote uptake via lipoprotein receptors in
the liver and elsewhere 7,63,97. By contrast there is a relative paucity of reports concerning
the synthesis of monomolecular conjugates of oligonucleotides with ligands designed to
target specific cell surface receptors. A few early studies on this topic involved folate-
conjugated antisense oligonucleotides that associated with the FRα receptor 98, N-acetyl
galactosamine conjugates that targeted the hepatic asialoglyoprotein receptor 99, and
conjugates of siRNA with Insulin-Like Growth Factor 1 for targeting its cognate
receptor 100.
More recently there has been a substantial increase in work on receptor targeting of
oligonucleotides. This includes our own reports on RGD peptide conjugates of splice
switching antisense oligonucleotides that can be delivered to melanoma cells via the αvβ3
integrin 31,101, as well as bombesin conjugates that are targeted to prostate cancer cells via
the BB2 receptor, a member of the G Protein-Coupled Receptor (GPCR) superfamily 102.
We have also targeted oligonucleotides to tumor cells using anisamide, a high affinity small
molecule ligand for the sigma receptor 103. Another interesting approach is the delivery of
siRNA by targeting TLRs 67. Thus an un-methylated CpG oligonucleotide known to bind to
TLR9 was chemically conjugated to a siRNA. This resulted in enhanced uptake by dendritic
cells, macrophages and B-cells, all known to express TLR9, as well as ‘knockdown’ of
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endogenous and reporter genes. Use in vivo of a CpG siRNA targeting the
immunosuppressive regulator Stat3 resulted in enhanced antitumor immune responses.
Another very promising approach to receptor specific delivery of oligonucleotides involves
use of nucleic acid aptamers 104. A pioneering report described the characterization of
chimeric oligonucleotides comprised of an aptamer that bound with high affinity to the
PMSA receptor in prostate cancer cells and siRNAs that affected key survival genes such as
Plk1 and Bcl2 105. These conjugates were taken up selectively by cells that expressed PSMA
receptor, were effective at ‘knockdown’ of the target messages in cell culture, and displayed
antitumor activity when locally administered. More recently a chemically optimized version
of a PMSA aptamer-Plk1siRNA chimera displayed antitumor activity against PMSA
expressing tumors when given by systemic administration 106. In another impressive study,
similar aptamer-siRNA chimeras inhibited tumor growth in vivo using siRNAs directed
against Upf2 and Smg1, two genes involved in nonsense mediate mRNA decay and thus in
immune regulation of tumors 107. Other important examples of aptamer-siRNAchimeras are
also beginning to emerge 108. These various studies have validated the concept that
monomeric ligand-oligonucleotide conjugates can produce significant pharmacological
effects both in cell culture and in animals, in the absence of any transfection agents. A recent
review has provided an extensive overview of receptor targeting of oligonucleotides 109.
Recent work on receptor-targeted oligonucleotide conjugates has also provided an important
new insight for the problem of effective delivery of antisense and siRNA molecules. The
essence is that the initial route of uptake (and subsequent trafficking) plays an important role
in determining the pharmacological effectiveness of the oligonucleotide. Thus in our studies
comparing effects of ‘free’ or receptor targeted SSOs, we consistently noted that the targeted
conjugates were more effective in attaining splice correction, even when the targeted and
free oligonucleotide were accumulated to the same level in cells 31,101,102. Studies with the
CpG siRNA conjugate revealed that the presence of TLR9 was critical for attaining effective
‘knockdown’ even though cells lacking the TLR could still take up the conjugate 67. This
also suggests a receptor specific aspect to intracellular trafficking and biological outcome.
These observations also harmonize with recent cell culture and in vivo studies of free
phosphorothioate oligonucleotides that suggest the co-existence of productive and non-
productive routes of internalization 53,110. These various observations support the concept
that it may be possible to optimize the effectiveness of an antisense or siRNA molecule by
controlling its pathway of uptake and intracellular trafficking, without resorting to harsh
cationic lipid or cationic polymer transfection agents.
Consequently, investigators interested in the design of new receptor-targeted oligonucleotide
conjugates should consider several basic issues. First, and most obvious, the ligand must
display high affinity for the receptor, preferably in the low nanomolar range. Second, in
order to achieve cell-type specific delivery there must be differential expression of the
receptor in the cell of interest as compared to other cell types. An initial estimate of relative
receptor expression in various tissues or between tumors and normal tissue can be gleaned
from contemporary gene expression data bases, at least at the mRNA level (for example,
http://www.ebi.ac.uk/gxa/). Third, in order to deliver sufficient quantities of oligonucleotide,
the receptor of interest must be relatively abundant. The abundance of various receptors can
range from a few copies per cell up to hundreds of thousands of copies. However, there are
relatively few compact sources for this type of information at the protein level, and thus the
literature must be searched for values for specific receptors. Fourth, the receptor of interest
must cycle efficiently between the plasma membrane and endosomes. There is information
in the literature on the propensity of various families of receptors to be internalized and
recycle. For example, different members of the integrin family can be internalized via
caveolae or via coated pits and be recycled via Rab4- or Rab11-dependent trafficking
processes 111. Agonist binding can stimulate the internalization of GPCRs via clathrin-
Juliano et al. Page 9













coated vesicles and their ultimate recycling to the plasma membrane or sorting to
multivesicular bodies for degradation in lysosomes 112. Receptor tyrosine kinases of the
EGF-R family also respond to agonist binding by internalization via the clathrin pathway
followed by trafficking to multivesicular bodies and lysosomes 113. Another important
consideration is the point at which the receptor-targeted oligonucleotide ceases to parallel
the intracellular trafficking of the receptor itself and enters separate pathways. It is not yet
clear which pathway of internalization and trafficking will be optimal for oligonucleotide
delivery, but it is clear that trafficking pathways must be taken into account. Thus the design
of novel targeted oligonucleotide conjugates should start with a clear picture of the
underlying receptor biology in order to have a reasonable chance of success.
5. Uptake and Trafficking of Oligonucleotides Associated with Nanocarriers
The most popular approach to enhancing delivery of antisense, siRNA or other types of
oligonucleotides is to incorporate the nucleic acid into some form of nanoparticle, with the
intent of overcoming biological barriers and increasing both cell uptake and escape from
membrane compartments 16,17,114,115. Lipid based carriers have proven to be very
efficacious for the delivery of siRNA to the liver 116, while a variety of polymeric
nanoparticles 117 and other types of nanocarriers 118 have also been developed for siRNA
delivery. Functional delivery of siRNA to tumors has been challenging, but recently targeted
lipid based nanoparticles have displayed substantial activity in this context 119. Nonetheless,
there remain concerns about possible toxicities associated with the cationic polymers or
lipids most commonly used to form nanocarriers for oligonucleotide delivery 120,121. Since
there is such a vast literature on use of nanoparticles as oligonucleotide delivery agents, we
will focus our discussion on a relatively few reports that have mechanistically addressed
issues of cellular uptake and trafficking.
a. Uptake and trafficking of non-targeted oligonucleotide nanocarriers
A very interesting report has challenged the conventional view that cationic lipid carriers
functionally deliver siRNA via endocytosis followed by escape from endosomes 122. This
group found that while much of the lipid and siRNA did enter cells by some form of
endocytosis, it was only a minor component of the cell-associated siRNA that contributed to
‘knock down’ function and that this component probably came from fusion between the
siRNA lipoplexes and the plasma membrane. This study is notable for going beyond
simplistic use of chemical inhibitors and employing molecular reagents such as dominant
negative versions of dynamin and caveolin to probe uptake pathways. Another interesting
recent study followed the uptake and trafficking of siRNA associated with perfluorocarbon
nanoparticles 123, finding that delivery was via formation of cell-nanoparticle hemifusion
complexes followed by lipid raft mediated internalization. This study made good use of the
strategy of co-localization with markers that are known to be internalized via particular
pathways. A recent investigation from our laboratory compared the uptake and trafficking
pathways of splice switching antisense oligonucleotides as delivered via cationic lipids or
via PEI, a cationic polymer 124. Several strategies including pharmacological inhibitors, co-
localization with known markers of internalization, as well as use of molecular reagents
were employed in this study. Interestingly, in agreement with the study on siRNA delivery
discussed above, functional delivery of antisense associated with lipoplexes was apparently
due to fusion at the plasma membrane, while delivery via polyplexes took place through an
unconventional form of endocytosis. Thus even with widely utilized transfection agents
there seems to be a diversity of delivery mechanisms that need to be better understood.
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b. Uptake and trafficking of targeted oligonucleotide nanocarriers
Over the last few years several very interesting forms of targeted nanoparticles have been
developed for purposes of siRNA delivery and some very impressive functional results have
been attained. For a review of some of the early literature see 79,125. However, there is a
dearth of information about the mechanistic aspects of the interplay of these particles with
cells. For example, some very high profile publications have described a strategy where a
chimeric polypeptide is formed between a targeting moiety and a cationic poly-arginine
sequence; the cationic sequence is used to complex siRNA while the targeting moiety
provides receptor selective delivery. Thus, a chimera including a rabies virus peptide that
binds an acetylcholine receptor was used to target siRNA to neuronal cells and demonstrated
therapeutic effects in a mouse model of viral encephalitis 126. In another study a single chain
antibody to the T cell protein CD7 was used as the targeting moiety and a siRNA cocktail to
CCR5 and to viral genes was used to inhibit HIV infection 127. This same general approach
has also been used to modulate inflammatory conditions, and the growth of other
viruses 128,129. However, these various studies provide no information on the mechanism of
cellular uptake and subsequent trafficking of these interesting chimeric complexes. A
somewhat similar strategy involved complexation of siRNA to chimeric fusion proteins that
included a single chain antibody as the targeting moiety and a segment of protamine to bind
the nucleic acid. This strategy has been used in models of HIV and leukocyte
activation 130,131. However, despite very interesting functional data, once again there is little
information on the mechanism of delivery. Another interesting approach involves
preparation of a complex polymer that includes covalently attached siRNA, PEG, and a N-
acetylgalactosamine targeting ligand for interaction with the liver asialoglycoprotein
receptor 132. Similarly lactosylated PEG-siRNA conjugates formed into polyplexes have
been used to target hepatic carcinoma models 133. However, no substantial information on
trafficking is available concerning these hepatic targeting approaches. Lipid nanoparticles
incorporating anisamide, a small molecule ligand for the sigma receptor, have shown
promising effects in several animal tumor models 134,135 but only limited information is
available concerning uptake and trafficking. One type of targeted siRNA nanoparticle has
already been tested in the clinic in patients with solid tumors 136. The formulation is
comprised of siRNA against ribonucleotide reductase, a cationic cyclodextrin-containing
polymer, polyethylene glycol, and human transferrin as a targeting ligand. While some work
has been done concerning the cellular uptake 137 and overall biodistribution and tumor
uptake of these materials 138, there are few details concerning their intracellular trafficking.
Thus for targeted nanoparticles containing oligonucleotides there is a dearth of information
concerning the mechanistic details of the uptake and trafficking processes. Studies of this
type could help to make the future development of these materials more efficient
Conclusions
The thrust to develop antisense, siRNA, and other types of oligonucleotides as therapeutic
agents has, to some degree, outstripped our fundamental knowledge of how these molecules
behave in cells and in the body. While extensive information exists regarding the overall
pharmacokinetics and tissue distribution of both classic antisense and siRNA, we lack an
equivalent depth of knowledge about behavior at the cellular and intracellular level. This
deficit applies both to oligonucleotides administered in ‘free’ or ‘naked’ form and to these
molecules when incorporated into nanocarriers or conjugated to targeting ligands. Recent
work has provided some interesting and possibly surprising observations concerning the
uptake and intracellular trafficking of oligonucleotides. Thus conventional phosphorothioate
antisense molecules, which have been studied for years, turn out to have an unusual uptake
mechanism that involves both a productive and a less productive path to nuclear sites of
action. Work from our laboratory and from others has shown that the pharmacological
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effectiveness of an antisense or siRNA can strongly depend on its route of uptake and
trafficking. In particular, certain receptor-mediated processes seem to support productive
delivery. As the oligonucleotide therapeutics field matures, and particularly as investigators
seek to enhance specificity through targeted delivery, it will be important to employ basic
cell biological principles in the design of delivery approaches. This includes identification of
target receptors that are abundant, are differentially expressed, and are strongly linked to
endocytotic pathways. Further insights into the intracellular trafficking of oligonucleotides
will also facilitate the design of effective delivery systems.
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Figure 1. Pathways of Endocytosis and Trafficking
The figure illustrates several of the major internalization pathways discussed in the text.
Phagocytosis takes places only in specialized cells such as macrophages and granulocytes
while the other pathways are found in many cell types. A few of the key proteins involved in
some of the pathways are indicated; however many other proteins that play a role are not
depicted. Some aspects of the intracellular vesicular trafficking between various
endomembrane compartments are also illustrated. Specific Rab GTPases play key roles
controlling the flow of shuttle vesicles between individual compartments.
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Figure 2. Proposed Mechanism of Vesicular Trafficking of Oligonucleotides
Oligonucleotides are initially accumulated in an endomembrane compartment (the DONOR
compartment, for example, early endosomes) and are then trafficked by means of shuttle
vesicles to various other endomembrane compartments (the RECIPIENT compartment, for
example, the trans-Golgi). The first step (1) involves disjunction (‘pinching off’) of a shuttle
vesicle under the influence of a coat protein as well as other accessory proteins. At this stage
there are non-bilayer regions at the junction between the membranes of the DONOR
compartment and the shuttle vesicle. This provides an opportunity for some oligonucleotide
to escape to the cytosol. Step 2 involves uncoating of the coated vesicle; Rab proteins can
contribute to this step. Step 3 comprises movement of the shuttle vesicle toward its
destination along cytoskeletal tracks. Motor proteins such as various myosins (for the actin
system) or dyneins or kinesins (for the microtubular system) propel the vesicle. Rab proteins
are involved in forming the appropriate linkages to the cytoskeleton. Step 4 entails
recognition of the RECIPIENT (‘target’) compartment by the shuttle vesicle. Tether proteins
work with Rab proteins to provide interaction specificity while v-SNARE proteins in the
vesicle membrane interact with t-SNARE proteins in the RECIPIENT compartment
membrane to provide firm bridging, as well as contributing to specificity. In step 5 the
SNARE proteins undergo major conformational changes, and with the assistance of
accessory proteins, trigger fusion of the shuttle vesicle membrane with the membrane of the
RECIPIENT compartment. At this stage non-bilayer regions exist at the junction between
shuttle and RECIPIENT membranes potentially allowing escape of oligonucleotide.
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